Increased Transparency of Drug Research and Manufacturing Costs
New regulations aim to increase the transparency of drug clinical trial costs and pharmaceutical companies' research and development expenditures. This will give citizens access to information on how much it costs to develop a drug, potentially influencing discussions about drug prices and accessibility.
Key points
Companies conducting drug clinical trials will be required to publicly disclose detailed cost data for these trials, including per-patient costs and expenditures on personnel or materials.
Drug manufacturers will be obligated to report their total research and development expenditures, broken down by stages, from basic research to post-market studies.
This information will be available on dedicated websites, making it easier for citizens to understand how drug prices are determined.
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens
(explained here).
Start recording it now.